文献速递造血干细胞移植与细胞治疗血栓与止血贫血与红细胞疾病

含肠道器官移植后移植相关血栓性微血管病与免疫血液学并发症:逾100例连续病例经验

Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases.
PubMed 文献 · Br J Haematol · 2021-05-05

Descriptions of passenger lymphocyte syndrome (PLS), immune cytopenias and transplant-associated thrombotic microangiopathy (TA-TMA) after intestine-containing transplants remain scarce. We describe our centre's experience of these complications from 2007 to 2019.…

要点

  • PLS多见于ABO不合移植,本组9例均无需调整免疫抑制。
  • 免疫性血细胞减少常伴感染或静脉血栓,部分需利妥昔单抗等治疗。
  • TA-TMA需停用钙调神经磷酸酶抑制剂,部分需血浆置换或依库珠单抗。

核心结论

  • 含肠道器官移植后PLS、免疫性血细胞减少和TA-TMA虽不常见但可导致显著并发症。

主要发现

  • PLS发生9例(9%),中位移植后12天,均由ABO抗体引起,其中31例为次要ABO不合移植。
  • 免疫性血细胞减少患者中4/6需静脉抗生素治疗感染,3/6发生静脉血栓栓塞,3/6有明确继发原因。

关键数值与推荐

  • PLS中位发生时间为移植后12天,9例均无需改变免疫抑制方案。
  • 免疫性血细胞减少中位治疗4次(范围1-8),5/6使用利妥昔单抗,1例免疫性溶血需硼替佐米。
  • TA-TMA中2例接受血浆置换,1例血浆输注,1例依库珠单抗治疗。

临床怎么用

  • 含肠道器官移植后需监测ABO抗体相关PLS及免疫性血细胞减少。
  • 免疫性血细胞减少常合并感染和静脉血栓,应积极防治。
  • TA-TMA需及时停用钙调神经磷酸酶抑制剂并考虑血浆置换或补体抑制。

局限性

  • 单中心回顾性研究,样本量有限,结论需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Descriptions of passenger lymphocyte syndrome (PLS), immune cytopenias and transplant-associated thrombotic microangiopathy (TA-TMA) after intestine-containing transplants remain scarce. We describe our centre's experience of these complications from 2007 to 2019. Ninety-six patients received 103 transplants. PLS occurred in 9 (9%) patients (median 12 days post-transplant); all due to ABO antibodies. There were 31 minor ABO mismatch transplants. No patient required change in immunosuppression. Immune cytopenias (excluding PLS) occurred in six patients at an incidence of 1·7/100 patient years; three immune haemolysis, one immune thrombocytopenia, one acquired Glanzmann's and one immune neutropenia; 50% occurred with other cytopenias. All cases eventually responded to treatment, with a median of four treatments (range 1-8) and 5/6 were treated with rituximab. One patient with immune haemolysis required bortezomib. Complications were common in patients with immune cytopenias; 4/6 with infection needing intravenous antibiotics and 3/6 with venous thromboembolism. In 3/6 cases, a secondary cause for the immune cytopenia was evident. Switching from tacrolimus to ciclosporin was not necessary. There were five cases of transplant-associated thrombotic microangiopathy (TA-TMA; 1·5/100 patient years) requiring calcineurin inhibitor withdrawal; two cases associated with acute rejection. Two cases were managed with plasma exchange, one with plasma infusions and one with eculizumab. Further research in this patient group is required.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Thomas W, Foukaneli T, Cosgrove J, et al. Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases. Br J Haematol. 2021. PMID: 33954989. doi:10.1111/bjh.17430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。